PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions
Status: | Enrolling by invitation |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/22/2019 |
Start Date: | December 1, 2017 |
End Date: | February 25, 2022 |
This research study is evaluating how patients feel physically and emotionally after a prior
breast biopsy for specific breast conditions (including atypical lesions such as atypical
ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ
(LCIS), and/or ductal carcinoma in situ (DCIS))
breast biopsy for specific breast conditions (including atypical lesions such as atypical
ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ
(LCIS), and/or ductal carcinoma in situ (DCIS))
The goal of this research is to better understand the experience of women who have been
diagnosed with certain breast conditions to enable women (and their doctors) to make informed
decisions about their care.
diagnosed with certain breast conditions to enable women (and their doctors) to make informed
decisions about their care.
Inclusion Criteria:
Patients treated at DUMC, DFCI, MDACC, MGH, NWH, or DFCI @ SSH with a diagnosis of DCIS,
LCIS, ADH, or ALH who are also:
- Age 18 or more at index diagnosis
- Diagnosed with DCIS, LCIS, ADH, or ALH between January 1, 2012 and June 30, 2017
- Able to read either English or Spanish and able to provide written (via paper), or
on-line informed consent
- Treated and followed at one of the study sites (including affiliated network sites)
and for whom treatment and surveillance data are available, for at least 1 year of
follow up after date of diagnosis
- Participants with bilateral synchronous or metachronous disease (DCIS, LCIS, ADH, ALH)
are eligible
Exclusion Criteria:
- Ever had a diagnosis of invasive or microinvasive breast cancer
- DCIS prior to index lesion or history of progressive/recurrent DCIS after treatment
- Other cancers (excluding non-melanoma skin cancer) diagnosed within 5 years prior to
index lesion, including concurrent invasive cancer diagnosis and up to the present
time of participant's approach to invitation into the study
- Patients identified by treating physician as being unsuitable for contact
We found this trial at
1
site
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Ann H. Partridge, MD, MPH
Phone: 617-632-3800
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials